Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy

• Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key May 2026 meetings: Eyecelerator and Retinal Therapeutics Innovation Summit.
• No dose-limiting toxicities (DLTs) or drug-related serious adverse events (SAEs) have been reported within the scope of this interim analysis, to date in either low or high dose cohorts (n=3/cohort) post the single intravitreal injection.
• The high-dose cohort started at no light perception at baseline and all individuals recorded light perception or better within one month of the single intravitreal injection
• Dose-dependent results across multiple endpoints: Consistent trends observed across visual acuity, full-field stimulus testing (FST), and functional vision assessments including mobility and object recognition tasks
• Measurable logMAR visual acuity reported: One high-dose patient reported chart-based visual acuity measurable by the Berkeley Rudimentary Vision Test (BRVT)
• Collection of additional safety and efficacy data across broader patient populations is planned

Tokyo, Japan, May 1, 2026 - Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced the interim clinical results from its ongoing Phase 1/2 first-in-human trial of RV-001 in Japan. It will present the results at two premier events on May 1, 2026 in Denver, Colorado: Eyecelerator @ ARVO 2026 and the Retinal Therapeutics Innovation Summit, organized by the Foundation Fighting Blindness and the Casey Eye Institute at Oregon Health & Science University.

[Presentation Detail]

For further details, please check the press release below.
PR Newswire